Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
50–85
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Alzheimer's Disease patients - 50-85 years, mild to moderate AD: MMSE ≥16 and ≤ 26, clinical progression of AD over 12 months.
Healthy volunteers: - 50-75 years
BMI 18 and 30 m2/kg
Clinically normal physical findings including supine blood pressure and pulse rate.
You may not be if
Alzheimer's Disease patients - Clinically significant illness the 2 weeks prior to the administration of the PET ligand
Significant cerebrovascular disease or depression, central nervous system infarct or infection or lesions
Administration of any investigational product within 3 months prior to study and/or PET measurements for scientific purposes within the last 12 months.
Healthy volunteers - clinically significant illness within 2 weeks before administration of PET ligand, history of psychiatric or somatic disease/condition that may interfere, first degree relative with dementia. Obvious deterioration of memory functions.
